University Hospital, Bordeaux: Carcinoma trials

The registry lists 11 Carcinoma studies with University Hospital, Bordeaux as lead sponsor. 2 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 2 1Phase 3 1No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long Term Prediction of MASH-related HCC Risk by ProteomicsNot yet recruitingNCT07332611
• Stratification of Cutaneous Squamous Cell Carcinomas According to Its Transcriptomic, Metabolic and Inflammatory CharacteristicsRecruitingNCT06476964Not applicable
• Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase InhibitorsActive, not recruitingNCT05219318Phase 3
• Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC)CompletedNCT04222374
• Identification of Psychosocial Factors Associated With Diagnostic Delay in Advanced Basal Cell CarcinomaCompletedNCT04124796Not applicable
• Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)CompletedNCT03852238
• Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular CarcinomaCompletedNCT02834546
• Assessment of the Clinic-pathological Correlation of Basal Cell CarcinomaCompletedNCT02825511
• Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B CirrhosisCompletedNCT01357486Phase 2
• Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell CarcinomaCompletedNCT01339975
• A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before CystectomyTerminatedNCT01245660Early Phase 1